KetoSwiss AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
KetoSwiss AG - overview
Established
2017
Location
Basel, -, Switzerland
Primary Industry
Pharmaceuticals
About
Based in Switzerland, and founded in 2017 by its CEO Dr. Elena Gross, KetoSwiss AG operates as a biotechnology company that develops therapeutic products mitigating neurological diseases such as migraines and brain aging. In August 2023, KetoSwiss AG raised approximately EUR 4. 37 million in pre-series A funding led by William K.
Warren Foundation, with participation from Healthspan Capital and R42. KetoSwiss AG developed MigraKet, a product for the dietary management of migraine that contains micronutrients necessary for energy production in addition to macronutrients that are efficacious and close to the root cause of migraine. The MigraKet active substance is an endogenous metabolite – a Ketone body, that can be used by the human brain as an alternative source of fuel to glucose, when glucose utilization or transport is compromised.
Current Investors
William K. Warren Foundation, BaselArea.swiss, R42
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Mental Health Services, Therapeutic Devices, Pharmaceuticals
Website
www.keto.swiss
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.